BioMarin Pharmaceutical Inc.
BMRNNASDAQHealthcare● Active
$56.77
+$0.30(+0.53%)
Market Cap$11.0B
P/E Ratio—
52W High$66.28
52W Low$49.26
BioMarin Pharmaceutical Inc. (BMRN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BMRN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 4, 2026EPS Actual
$0.76
Est. $0.94 · -19.1%
Revenue
$0.77B
Est. $0.75B · +1.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 4, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
BMRN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.84B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.84B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | $0.96 | — | — | — | $0.93B | — |
| ▼ Q2 FY2026 | May 4, 2026 | $0.94 | $0.76 | -19.1% | $0.77B | $0.75B | +1.8% |
| ▼ Q1 FY2026 | Feb 23, 2026 | $0.17 | -$0.24 | -241.7% | $0.87B | $0.83B | +4.9% |
| ▲ Q4 FY2025 | Oct 27, 2025 | -$0.15 | $0.12 | +180.0% | $0.78B | $0.82B | -5.8% |
| ▲ Q3 FY2025 | Aug 4, 2025 | $0.86 | $1.44 | +67.3% | $0.83B | $0.76B | +8.3% |
| ▲ Q2 FY2025 | May 1, 2025 | $0.94 | $1.13 | +20.2% | $0.75B | $0.76B | -2.3% |
| ▲ Q1 FY2025 | Feb 19, 2025 | $0.54 | $0.92 | +70.4% | $0.74B | $0.71B | +3.6% |
| ▲ Q4 FY2024 | Oct 29, 2024 | $0.78 | $0.91 | +16.7% | $0.75B | $0.71B | +4.7% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
$0.96
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 4, 2026Miss
EPS Actual
$0.76
EPS Est.
$0.94
EPS Surpr.
-19.1%
Revenue
$0.77B
Q1 FY2026
Feb 23, 2026Miss
EPS Actual
-$0.24
EPS Est.
$0.17
EPS Surpr.
-241.7%
Revenue
$0.87B
Q4 FY2025
Oct 27, 2025Beat
EPS Actual
$0.12
EPS Est.
-$0.15
EPS Surpr.
+180.0%
Revenue
$0.78B
Q3 FY2025
Aug 4, 2025Beat
EPS Actual
$1.44
EPS Est.
$0.86
EPS Surpr.
+67.3%
Revenue
$0.83B
Q2 FY2025
May 1, 2025Beat
EPS Actual
$1.13
EPS Est.
$0.94
EPS Surpr.
+20.2%
Revenue
$0.75B
Q1 FY2025
Feb 19, 2025Beat
EPS Actual
$0.92
EPS Est.
$0.54
EPS Surpr.
+70.4%
Revenue
$0.74B
Q4 FY2024
Oct 29, 2024Beat
EPS Actual
$0.91
EPS Est.
$0.78
EPS Surpr.
+16.7%
Revenue
$0.75B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $1.55 | $1.73 | $2.01 | 4 |
| Q3 FY2027 | $1.47 | $1.64 | $1.90 | 8 |
| Q2 FY2027 | $1.42 | $1.58 | $1.84 | 5 |
| Q1 FY2027 | $1.29 | $1.44 | $1.67 | 4 |
| Q4 FY2026 | $1.58 | $1.76 | $2.05 | 4 |
| Q3 FY2026 | $1.35 | $1.49 | $1.58 | 11 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $1.1B | $1.2B | $1.3B | 7 |
| Q3 FY2027 | $1.0B | $1.1B | $1.3B | 8 |
| Q2 FY2027 | $1.0B | $1.1B | $1.2B | 7 |
| Q1 FY2027 | $1.0B | $1.1B | $1.2B | 11 |
| Q4 FY2026 | $1.0B | $1.1B | $1.3B | 11 |
| Q3 FY2026 | $1.0B | $1.1B | $1.1B | 14 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 4, 2026 | -19.1% | $54.06 | $55.46 | +2.59% |
| ▼ Q1 FY2026 | Feb 23, 2026 | -241.7% | $64.08 | $62.92 | -1.81% |
| ▲ Q4 FY2025 | Oct 27, 2025 | +180.0% | $54.48 | $52.67 | -3.32% |
| ▲ Q3 FY2025 | Aug 4, 2025 | +67.3% | $58.14 | $60.31 | +3.73% |
| ▲ Q2 FY2025 | May 1, 2025 | +20.2% | $63.69 | $62.71 | -1.54% |
| ▲ Q1 FY2025 | Feb 19, 2025 | +70.4% | $64.86 | $65.61 | +1.16% |
| ▲ Q4 FY2024 | Oct 29, 2024 | +16.7% | $70.13 | $69.91 | -0.31% |
| ▲ Q3 FY2024 | Aug 5, 2024 | +168.3% | $84.20 | $80.47 | -4.43% |
Q2 FY2026+2.59%
Report Date
May 4, 2026
EPS Beat/Miss
-19.1%
Price Before
$54.06
Price After
$55.46
Q1 FY2026-1.81%
Report Date
Feb 23, 2026
EPS Beat/Miss
-241.7%
Price Before
$64.08
Price After
$62.92
Q4 FY2025-3.32%
Report Date
Oct 27, 2025
EPS Beat/Miss
+180.0%
Price Before
$54.48
Price After
$52.67
Q3 FY2025+3.73%
Report Date
Aug 4, 2025
EPS Beat/Miss
+67.3%
Price Before
$58.14
Price After
$60.31
Q2 FY2025-1.54%
Report Date
May 1, 2025
EPS Beat/Miss
+20.2%
Price Before
$63.69
Price After
$62.71
Q1 FY2025+1.16%
Report Date
Feb 19, 2025
EPS Beat/Miss
+70.4%
Price Before
$64.86
Price After
$65.61
Q4 FY2024-0.31%
Report Date
Oct 29, 2024
EPS Beat/Miss
+16.7%
Price Before
$70.13
Price After
$69.91
Q3 FY2024-4.43%
Report Date
Aug 5, 2024
EPS Beat/Miss
+168.3%
Price Before
$84.20
Price After
$80.47
Avg Beat Reaction-0.79%
Avg Miss Reaction+0.39%
Beat Rate6 / 8 quarters
Largest Move-4.43% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BMRN ends December
BioMarin Pharmaceutical Inc. (BMRN) most recently reported earnings on May 4, 2026 for Q2 FY2026, posting EPS of $0.76 — missing the analyst consensus of $0.94 by -19.1%. The next BMRN earnings date is expected around September 1, 2026.
Each quarter, investors track BMRN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BMRN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BMRN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BMRN earnings · 5 questionsBioMarin Pharmaceutical Inc.'s next earnings report is expected around September 1, 2026. BMRN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BMRN historically reports after market close (AMC).
BMRN earnings datewhen is BMRN earningsBMRN next earnings datewhen does BMRN report earningsBMRN earnings calendar
▸ Source: FMP · BioMarin Pharmaceutical Inc. SEC filings · US GAAP · BioMarin Pharmaceutical Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026